Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage

Molecular and Cellular Biology

Volumn 16, Issue 3, 1996, Pages 1126-1137

  Moll, Ute M ^a   Ostermeyer, Anne G ^a   Haladay, Robert ^a   Winkfield, Blonka ^a   Frazier, Mark ^b   Zambetti, Gerard ^b  

^a STONY BROOK UNIVERSITY   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL GROWTH; CYTOPLASM; DNA DAMAGE; DNA STRAND BREAKAGE; ENZYME INHIBITION; GENE INDUCTION; GENE MUTATION; GENE TRANSLOCATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN METABOLISM; TUMOR SUPPRESSOR GENE;

EID: 0030048389     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.16.3.1126     Document Type: Article

References (71)

1. Bueso-Ramos, C. E., T. Manshouri, M. A. Haidar, Y. O. Huh, M. J. Keating, and M. Albitar. 1995. Multiple patterns of MDM-2 deregulation in human leukemias: implications in leukemogenesis and prognosis. Leukemia Lymphomas 17:13-18.
2. Chen, J. W., Y. Cha, K. U. Yuksel, R. W. Gracy, and J. T. August 1988. Isolation and sequencing of a cDNA clone encoding lysosomal membrane glycoprotcm mLAMP-1; sequence similarity to proteins bearing onco-differentiation antigens. J Biol. Chem. 263:8754-8758.
3. Chen, Y., C.-F, Chen, D. J. Riley, D. C. Allred, P.-L. Chen, D. Von Hoff, C. K. Osborne, and W.-H. Lee. 1995. Aberrant subcellular localization of BRCA 1 in breast cancer. Science 270:789-791.
4. Davidoff, A. M., J. D. Iglehart, and J. R. Marks. 1992. Immune response to p53 is dependent upon p53/HSP 70 completes in breast cancers. Proc. Natl. Acad. Sci. USA 89:3439-3442.
5. Davidoff, A. M., J. C. Pence, N. A. Shorter, J. D. Iglehart, and J. R. Marks. 1992 Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines. Oncogene 7:127-133.
6. Debbas, M., and E. White. 1993. Wild-type p53 mediates apoptosis by E1A which is inhibited by E1B. Genes Dev 7:546-554
7. Demers, W., S. A. Foster, C. L. Halbert, and D. A. Galloway. 1994. Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc. Natl. Acad. Sci. USA 91:4382-4386.
8. Eady, J. J., and J. H. Peacock. 1992. Host cell reactivation of gamma-irradiated adenovirus 5 in human cell lines of varying radiosensitivity. Br. J. Cancer 66:113-118.
9. El-Deiry, W. S., S. E. Kern, J. A. Pietenpol, K. W. Kinzler, and B. Vogelstein. 1992. Definition of a consensus binding site for p53. Nat. Genet. 1:45-49.
10. El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF 1, a potential mediator of p53 suppression. Cell 75:817-825
11. Feitelson, M. A., M. Zhun, L. X. Duan, and W. T. London. 1993. Hepatitis B X antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 8:1109-1117.
12. Fontoura, B. M. A., E. A. Sorokina, E. David, and R. B. Carroll. 1992. P53 is covalently linked to 5.8S rRNA. Mol. Cell. Biol. 12:5145-5151.
13. Funk, W. D., D. T. Pak, R. H. Karas, W. E. Wright, and J. W. Shay. 1992. A transcriptionally active DNA binding site for human p53 protein complexes. Mol. Cell. Biol. 12:2866-2871.
14. Gannon, J. V., and D. P. Lane. 1991. Protein synthesis required to anchor a mutant p53 protein which is temperature-sensitive for nuclear transport Nature (London) 349:802-806.
15. Ginsberg, D., D. Michael-Michalovitz, D. Ginsberg, and M. Oren. 1991. Induction of growth arrest by a temperature-sensitive p53 mutant is correlated with increased nuclear localization and decreased stability of the protein. Mol. Cell. Biol. 11:582-585.
16. Green, J., G. Griffith, D. Louvard, P. Quinn, and G. Warren. 1981. Passage of viral membrane proteins through the Golgi complex. J. Mol. Biol. 152: 663-698
17. Gusterson, B. A., R. Anbazhagan, W. Warren, C. Midgely, D. P. Lane, M. O'Hare, A. Stamps, R. Carter, and H. Jayatilake. 1991. Expression of p53 in premalignant and malignant squamous epithelium. Oncogene 6:1785-1789.
18. Halperin, E. C., and E. B. Cox. 1986. Radiation therapy in the management of neuroblastoma: the Duke University Medical Center experience from 1967-1984. Int J. Radiat. Oncol. Biol. Phys. 12:1829-1837.
19. Harper, J. W., G. R. Adam, N. Wei, K. Keyomars, and S. J. Elledge. 1993. The p21 Cdk-interacting protein Cip 1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816.
20. Harris, C. C., and M. Hollstein. 1993. Clinical implication of the p53 tumor suppressor gene. N. Engl. J. Med. 329:1318-1327.
21. Hinds, P. W., C. A. Finlay, A. B. Frey, and A. J. Levine. 1987. Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53-plus-ras-transformed cell lines. Mol. Cell. Biol. 7:2863-2869.
22. Hollstein, M., K. Rice, M. S. Greenblatt, T. Soussi, R. Fuchs, T. Sortie, E. Hovig, B. Smith-Sorensen, R. Montesano, and C. C. Harris. 1994. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 22:3551-3555.
23. James, M., and J. Mansbridge. 1982. Ultraviolet radiation sensitivity of proliferating and differentiated human neuroblastoma cells. Int. J. Radiat. Biol. 41:547-556.
24. Juven, T., Y. Barak, A. Zauberman, D. L. George, and M. Oren. 1993. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 8:3411-3416.
25. Kastan, M. B., O. Onyekwere, D. Sidransky, B. Vogelstein, and R. W. Craig. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311.
26. Kastan, M. B., Q. Zhan, W. S. El-Deiry, F. Carrier, T. Jacks, W. V. Walsh, B. S. Plunkett, B. Vogelstein, and A. J. Fornace, Jr. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and gadd 45 is defective in ataxia telangiectasia Cell 71:587-597.
27. Koop, C. E., and L. Schnaufer. 1975. The management of abdominal neuroblastomas Cancer 35:905-909.
28. Kruman, I. I., M. A. Kostenko, R. Y. Gordon, V. I. Popov, and S. R. Umansky. 1993 Differentiation and apoptosis of murine neuroblastoma N1E115. Biochem. Biophys. Res. Commun 191:1309-1318.
29. Kulesz-Martin, M. F., B. Lisafeld, H. Huang, N. D. Kisiel, and L. Lee. 1994. Endogenous p53 protein generated from wild type alternatively spliced p53 RNA in mouse epidermal cells. Mol. Cell, Biol. 14:1698-1708.
30. Lane, D. P. 1992 p53, the guardian of the genome. Nature (London) 358: 15-16.
31. Lane, D. P., and S. Benchimol. 1990. P53: oncogene or anti-oncogene? Genes Dev 4:1-8.
32. Lin, D., M. Fiscella, P. M. O'Connor, J. Jackman, M. Chen, L. L. Luo, A. Sala, S. Travail, E. Appella, and W. E. Mercer. 1994. Constitutive expression of B-myb can bypass p53-induced WAF1/Cip 1-mediated G1 arrest. Proc Natl. Acad. Sci. USA 91:10079-10083.
33. Livingstone, A., R. J. Mairs, J. Russell, J. O'Donoghue, M. N. Gaze, and T. E. Wheldon. 1994. N-myc gene copy number in neuroblastoma cell lines and resistance to experimental treatment. Eur. J. Cancer 30A:382-389.
34. Livingstone, L. R., A. White, J. Sprouse, E. Livanos, T. Jacks, and T. D. Tlsty. 1992. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923-935.
35. Lu, X., and D. P. Lane. 1993. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell 75:765-778.
36. Martinez, J., I. Georgoff, J. Martinez, and A. J. Levine. 1991. Cellular localization and cell cycle regulation by a temperature sensitive p53 protein. Genes Dev. 5:151-159
37. McMillan, T. J., A. M. Cassoni, S. Edwards, A. Holmes, and J. H. Peacock. 1990. The relationship of DNA double strand break induction to radiosensitivity in human tumor cell lines. Int. J. Radiat. Biol. 58:427-438.
38. Melino, G., M. Annicchiarico-Petruzelli, L. Piredda, E. Candi, V. Gentile, P. J. Davies, and M. Piacentini. 1994. Tissue transglutaminase and apoptosis: sense and antisense transfection studies with human neuroblastoma cells. Mol Cell Biol. 14:6584-6596.
39. Michieli, P., M. Chedid, D. Lin, H. Pierce, W. E. Mercer, and D. Givol. 1994. Induction of WAF1/CIP 1 by a p53-independent pathway. Cancer Res. 54: 3391-3395
40. Mietz, J. A., T. Unger, J. M. Huibregtse, and P. M. Howley. 1992. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J. 11:5013-5020.
41. Moll, U. M. Unpublished data.
42. Moll, U. M., et al. Unpublished data.
43. Moll, U. M., M. LaQuaglia, J. Benard, and G. Riou. 1995. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc. Natl. Acad. Sci. USA 92: 4407-4411.
44. Moll, U. M., G. Riou, and A. J. Levine. 1992. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. Natl. Acad. Sci. USA 89:7262-7266.
45. Momand, J., G. P. Zambetti, D. C. Olson, D. George, and A. J. Levine. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245
46. Negrini, M., S. Sabbioni, S. Haldar, L. Possati, A. Castagnoli, A. Corallini, G. Barbanti-Brodano, and C. Croce. 1994. Tumor and growth suppression of breast cancer cells by chromosome 17-associated functions. Cancer Res. 54: 1818-1824.
47. Nelson, W. G., and M. B. Kastan. 1994. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol. 14:1815-1823.
48. Noda, A., Y. Ning, S. F. Venable, O. M. Pereira-Smith, and J. R. Smith. 1994. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen Exp. Cell Res. 211:90-98.
49. Oliner, J. D., K. W. Kinzler, P. S. Meltzer, D. L. George, and B. Vogelstein. 1992. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (London) 358:80-83.
50. Oren, M., W. Maltzman, and A. J. Levine. 1981. Posttranslational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol. Cell. Biol. 1:101-110.
51. Prives, C., J. Bargonetti, G. Farmer, E. Ferrari, P. Friedlander, L. Jayaraman, Y. Wang, N. Pavletich, and U. Hubscher. 1994. DNA-binding properties of the p53 tumor suppressor protein. Cold Spring Harbor Symp. Quant. Biol. 59:207-213
52. Sidell, N., and H. P. Koeffler. 1988 Modulation of Mr 53,000 protein with induction of differentiation of human neuroblastoma cells. Cancer Res. 48: 2226-2230
53. Scheffner, M., B. A. Werness, M. Huibregtse, A. J. Levine, and P. M. Howley. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136
54. Shaulsky, G., A. Ben-Ze'ev, and V. Rotter. 1990. Subcellular distributions of the p53 protein during the cell cycle of Balb/C 3T3 cells. Oncogene 5: 1707-1711.
55. Shaulsky, G., N. Goldfinger, A. Ben-Ze'ev, and V. Rotter. 1990. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumongenesis. Mol. Cell. Biol. 10:6565-6577.
56. Shaulsky, G., N. Goldfinger, A. Peled, and V. Rotter. 1991. Involvement of wild-type p53 protein in the cell cycle requires nuclear localization. Cell Growth Differ. 2:661-667
57. Shaulsky, G., N. Goldfinger, M. Tosky, A. J. Levine, and V. Rotter. 1991. Nuclear localization is essential for the activity of p53 protein. Oncogene 6: 2055-2065.
58. Speir, E., R. Modaki, E. S. Huang, M. B. Leon, F. Shawl, T. Kinkel, and S. E. Epstein. 1994. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 265:391-394.
59. Takahashi, K., H. Sumimoto, K. Suzuki, and T. Ono. 1993. Protein synthesis-dependent cytoplasmic translocation of p53 protein after serum stimulation of growth-arrested MCF-7 cells. Mol. Carcinog. 8:58-66.
60. Takahashi, T., M. M. Nam, I. Chiba, M. J. Birrer, R. K. Rosenberg, M. Vinocour, M. Levitt, H. Pass, A. F. Gazdar, and J. D. Minna. 1989. P53: a frequent target for genetic abnormalities in lung cancer. Science 246:491-494.
61. Ueda, H., S. J. Ullrich, J. D. Gangemi, C. A. Rappel, L. Ngo, M. A. Feitelson, and G. Jay. 1995. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat. Genet. 9:41-44.
62. Wagner, I., H. Arlt, L. van Djck, T. Langer, and W. Neupert. 1994. Molecular chaperones cooperate with PIM 1 protease in the degradation of misfolded proteins in mitochondria. EMBO J. 13:5135-5145.
63. Wang, X. W., K. Forrester, H. Yeh, M. A. Feitelson, J.-R. Gu, and C. C. Harris. 1994 Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity and association with transcription factor ERCC 3. Proc. Natl. Acad. Sci. USA 91:2230-2234.
64. White, E. 1994 P53, guardian of Rb. Nature (London) 371:21-22
65. Vindelov, L. L., I. J. Christensen, and N. I. Nissen. 1983. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3:323-327.
66. Vojtesek, B., and D. P. Lane. 1993. Regulation of p53 protein expression in human breast cancer cell lines. J. Life Sci. 105:607-612.
67. Wu, X., J. H. Bayle, D. Olson, and A. J. Levine. 1993. The p53-mem2 autoregulatory feedback loop. Genes Dev. 7:1126-1132.
68. Xiong, Y., G. J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach. 1993 P21 is a universal inhibitor of cyclin kinases Nature (London) 366: 701-704.
69. Yew, P. R., and A. J. Berk. 1992. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature (London) 357: 82-85.
70. Yewdell, J. W., J. V. Gannon, and D. P. Lane. 1986. Monoclonal antibody analysis of p53 expression in normal and transformed cells. J. Virol. 59: 444-452.
71. Yin, Y., M. A. Tainsky, F. Z. Bischoff, L. Z. Strong, and G. M. Wahl. 1992. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles Cell 70:937-948